This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is no longer recruiting patients. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. This Phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma. All patients will receive infusions of combination chemotherapy for 1-3 days during Weeks 1, 3, 6-7, and 9-10. Patients younger than 2 months old will also receive injections of filgrastim or sargramostim beginning 24 hours after completing chemotherapy and continuing until blood counts return to normal. Some patients may continue to receive combination chemotherapy in Weeks 12-13, 15, 18-19, and 21. Following completion of chemotherapy, patients will undergo surgery to remove residual tumor. Some patients may then receive radiation therapy. Patients will receive follow-up evaluations once a month for 6 months, every 2 months for 6 months, every 3 months for 1 year, every 6 months for 1 year, and once a year thereaf
Showing the most recent 10 out of 459 publications
